GlassScriptPhysician profile
Anthony Nguyen
NPI 1841519915
$9,239.85
in general payments reported to CMS, 2019-2025
37 companies · $4,163 in 2025
The $4,163 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $337 · 2021: $700 · 2022: $845 · 2023: $1,424 · 2024: $752 · 2025: $4,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,051 · Education: $265 · Consulting Fee: $23.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,051.43 |
| Education | $264.75 |
| Consulting Fee | $23.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,805.70 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,072.28 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,012.95 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $925.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $490.96 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $241.68 | 2025 | Neffy |
| Csl Behring | $212.74 | 2019-2024 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $207.49 | 2021-2025 | Takhzyro, Eohilia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.94 | 2019-2022 | |
| Pfizer INC. | $178.33 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $171.98 | 2023-2025 | |
| Alk-Abello, INC | $162.51 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Blueprint Medicines Corporation | $154.68 | 2023 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $149.63 | 2025 | Dupixent |
| Galderma Laboratories, L.P. | $146.01 | 2025 | Nemluvio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $140.05 | 2019-2024 | Auvi-Q |
| Amgen INC. | $139.98 | 2019-2025 | Tezspire |
| Lilly USA, LLC | $121.55 | 2025 | Ebglyss |
| Stryker Corporation | $118.14 | 2019 | |
| Horizon Therapeutics Plc | $105.99 | 2019-2022 | |
| Grifols USA, LLC | $75.07 | 2022-2025 | Xembify |
| Biocryst US Sales Co., LLC | $65.90 | 2025 | Orladeyo |
| Genentech USA, INC. | $52.48 | 2023-2024 | Xolair |
| Cycle Pharmaceuticals INC | $46.27 | 2025 | Sajazir |
| Octapharma USA, INC. | $40.26 | 2023-2024 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $39.74 | 2021 | |
| Daiichi Sankyo INC. | $27.00 | 2025 | Injectafer |
| Adma Biomanufacturing LLC | $23.47 | 2025 | |
| Pharming Healthcare, INC. | $17.90 | 2025 | Ruconest |
| Optinose US, INC. | $17.54 | 2023 | |
| Abbvie INC. | $17.22 | 2021 | |
| Hikma Pharmaceuticals USA | $15.09 | 2023 | Ryaltris |
| Circassia INC. | $13.55 | 2019 | |
| Allergan, INC. | $13.04 | 2019 | |
| Phadia US INC. | $12.02 | 2019 | |
| Sanofi Pasteur INC. | $11.76 | 2020 | |
| Merck Sharp & Dohme LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.